KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Share-based Compensation (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Share-based Compensation data on record, last reported at $157.6 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 6.08% year-over-year to $157.6 million; the TTM value through Dec 2025 reached $685.9 million, down 1.8%, while the annual FY2025 figure was $685.9 million, 1.8% down from the prior year.
  • Share-based Compensation reached $157.6 million in Q4 2025 per VRTX's latest filing, down from $194.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $208.6 million in Q4 2023 and bottomed at $103.0 million in Q3 2021.
  • Average Share-based Compensation over 5 years is $144.9 million, with a median of $133.2 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: surged 87.09% in 2023, then dropped 19.56% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $118.6 million in 2021, then decreased by 5.99% to $111.5 million in 2022, then surged by 87.09% to $208.6 million in 2023, then decreased by 19.56% to $167.8 million in 2024, then fell by 6.08% to $157.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $157.6 million in Q4 2025, $194.9 million in Q3 2025, and $167.3 million in Q2 2025.